Oculus Go is enabling users to their canceled travels with a virtual getaway. Image courtesy of Oculus Go

While rising coronavirus cases in the area have canceled so many summer vacations, not all hope of sightseeing this summer is lost. A Houston entrepreneur has created a virtual alternative.

Houston-area industrial design startup, Armstrong Innovations launched two Oculus Go app games, aptly named 'Escape'. The VR app was designed with relaxation and meditation in mind but has doubled as a new way to relax and sightsee without leaving your home during the COVID-19 pandemic.

"The sights and sounds of our new app assist with mindfulness and meditation," says CEO and founder Derek Armstrong. "It's about focusing on the sights and sounds, especially with the virus growing. It's a quick getaway without having to physically go anywhere."

The project began a year ago and was completed in March — right at the start of stay-at-home orders that paralyzed everyday life before launching this month. The company's new array of Occulus Go experiences aims at easing the mind and spirits, but with the rise of coronavirus 'Escape' can also serve to calm frayed nerves.

The app is based on popular view master toys and stereoscopes from the 1800s that are reminiscent of exploration tools used over the years. There are two different experiences to choose from one named 'Escape: Roma' for its old-world inspired poolside lounge and another named 'Escape: Utopia', which brings outer space to life in front of an Oculus user's eyes.

"The app has already gotten a lot of traction in places where people are not able to go out in the world," says Armstrong. "It's so easy just to pop on your Oculus headset, open the app, and zone out or relax for a few minutes."

The local industrial design startup was founded in 2018, and it has already released a few music packs with tracks ranging from horror titles to 8-bit retro remakes for Unreal Engine projects, an advanced real-time 3D creation tool that serves as a game engine for creators to deliver interactive experiences. The music packs are a collection of audio assets made in collaboration with Epic Games.

"Our company is focused on creating engaging gamified experiences," says Armstrong. "The inspiration for our packs and now our new app came from my interest in treating PTSD and how virtual reality can help ease the symptoms of anxiety in some cases."

Armstrong, a Houston native, describes himself as a "maker of stuff," with previous experience in music production and a passion for design. According to him, his hometown is the best place to be.

"Houston really has everything you need, when it comes to new innovations and technology," says Armstrong. "I would prefer to have my business rooted in Houston rather than moving to a design startup hotspot."

Armstrong Innovations hopes to grow into new areas of the industrial design world, especially in military-driven technologies and other video game opportunities in the next year or so. Product keys for 'Escape' can be purchased online now, available worldwide for maximum relaxation.


Derek Armstrong, a Houston native, founded his design company, Armstrong Innovations. Photo courtesy of Oculus Go

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”